TMS (and treatments)

Recent articles

A patient receives transcranial magnetic stimulation.

Magnetic stimulation for autism: Q&A with Xujun Duan

A new individualized approach to transcranial magnetic stimulation may one day be an effective treatment for social and communication difficulties, if the results from Duan’s small preliminary trial pan out.

By Angie Voyles Askham
11 September 2023 | 6 min read
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Modified MRI; father findings

This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.

By Emily Harris
22 June 2023 | 4 min read
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again

This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.

By Emily Harris
10 November 2022 | 5 min read

Transcranial treatment; maternal inflammation; autism ants and more

Transcranial treatment may bolster memory in adults with autism, inflammatory molecule may alter an emotional brain region in newborns, and examining ants could yield insights into autism

By Emily Willingham
18 August 2017 | 4 min read

Explore more from The Transmitter

Cell population in brainstem coordinates cough, new study shows

The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.

By Calli McMurray
6 September 2024 | 5 min read
Capitol building
Spectrum Microphone

In updated U.S. autism bill, Congress calls for funding boost, expanded scope

The current Autism CARES Act sunsets in late September.

By Rachel Zamzow
5 September 2024 | 5 min listen
Illustration of ketamine blocking open ion channels in active NMDA receptors, quieting the cells and disrupting downstream signaling involved in depression.

Ketamine targets lateral habenula, setting off cascade of antidepressant effects

The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.

By Olivia Gieger
4 September 2024 | 6 min read